HuGE Literature Finder
Records 1-7
CYP2A6 Polymorphisms Associate with Outcomes of S-1 Plus Oxaliplatin Chemotherapy in Chinese Gastric Cancer Patients.
Genomics, proteomics & bioinformatics 2017 Aug . Yang Lin, Zou Shanshan, Shu Chang, Song Yan, Sun Yong-Kun, Zhang Wen, Zhou Aiping, Yuan Xinghua, Yang Yi, Hu Songni |
A phase II study of preoperative chemoradiation with tegafur-uracil plus leucovorin for locally advanced rectal cancer with pharmacogenetic analysis.
Radiation oncology (London, England) 2017 Mar 12 (1): 62. Kim Sun Young, Baek Ji Yeon, Oh Jae Hwan, Park Sung Chan, Sohn Dae Kyung, Kim Min Ju, Chang Hee Jin, Kong Sun-Young, Kim Dae Yo |
Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer.
Cancer chemotherapy and pharmacology 2013 Nov 72 (5): 953-64. Park Sook Ryun, Hong Yong Sang, Lim Hyeong-Seok, Seong Moon-Woo, Kong Sun-Young, Kim Sun Young, Park Young-Iee, Jung Kyung H |
Associations of various gene polymorphisms with toxicity in colorectal cancer patients receiving oral uracil and tegafur plus leucovorin: a prospective study.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2011 Feb 22 (2): 355-61. Tsunoda A, Nakao K, Watanabe M, Matsui N, Ooyama A, Kusano |
A phase I/II study of combination therapy of S-1 and irinotecan in patients with previously untreated metastatic or recurrent colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009 May 27 (15_suppl): e15023. Choi Y, Kim T, Lee S, Lee J, Chang H, Kim H, Shin J, Lee J, Kang |
Pharmacokinetic and pharmacogenetic study of S-1 in Korean patients with metastatic biliary cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009 May 27 (15_suppl): 2505. Kim K, Jang G D, Lim H S, Kim H S, Shin J G, Lee J L, Ryu M H, Chang H M, Kang Y K, Kim T |
[Validation of genetic polymorphisms associated to the toxicity of chemotherapy in colorectal cancer patients].
Farmacia hospitalaria : órgano oficial de expresión científica de la Sociedad Española de Farmacia Hospitalaria 0 38 (4): 283-90. Cortejoso L, García M I, García-Alfonso P, Grávalos C, Robles L, González-Haba E, Sanjurjo M, López-Fernández L |
- Page last reviewed:Oct 1, 2020
- Page last updated:Jan 19, 2021
- Content source: